Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14048484 | 0.85 | CDC25B (0.55) | CDC25BMEN1KMT2AFABP4ALDH1A1 | |
| SCHEMBL4594987 | 0.78 | CDC25B (0.71) | CDC25BMEN1KMT2ACTSVCTSL | |
| SCHEMBL14030692 | 0.78 | CDC25B (0.63) | CDC25BMEN1KMT2ACTSVCTSL | |
| SCHEMBL4593706 | 0.75 | CDC25B (0.74) | CDC25BMEN1KMT2AFABP4 | |
| SCHEMBL4594364 | 0.75 | CDC25B (0.62) | CDC25BMEN1KMT2AFABP4PLK1 | |
| SCHEMBL4594920 | 0.73 | CDC25B (0.67) | CDC25BMEN1KMT2AALDH1A1PLK1 | |
| SCHEMBL4594590 | 0.72 | RAB9A (0.64) | CDC25BMEN1KMT2AALDH1A1HSP90AA1 | |
| SCHEMBL8943966 | 0.72 | CDC25B (0.55) | CDC25BMEN1KMT2ACTSVCTSL | |
| Hydrochloric Acid SCHEMBL809061 | 0.72 | CDC25B (0.54) | CDC25BMEN1KMT2AALDH1A1HSP90AA1 | |
| SCHEMBL468013 | 0.71 | MEN1 (0.58) | MEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | APP, BACE1, SNCA | CDC25B 2914/4885MEN1 2044/4885KMT2A 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.